TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of No-Calorie Sweetened Beverages Within a Weight Loss Behavior Change Program and During Subsequent Weight Maintenance
Brief Summary: The no calorie drink study is looking for over 300 people to participate. The study is evaluating the effect of no calorie beverages on weight loss and weight maintained over time in people who drink diet beverages every day as compared to water only drinkers during the 1 year study period.


Options:
A: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
B: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
C: Arm Label: Non Nutritive Sweetened Beverages; Type: EXPERIMENTAL; Interventions: Other: Non Nutritive Sweetened Beverages | Arm Label: Control Water Beverages; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Non Nutritive Sweetened Beverages; Assigned to Arm(s): Non Nutritive Sweetened Beverages | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control Water Beverages
D: Arm Label: No calorie beverages; Type: EXPERIMENTAL; Interventions: Behavioral: 2 no calorie beverages per day | Arm Label: Water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 water beverages per day | Intervention Type: BEHAVIORAL; Name: 2 no calorie beverages per day; Assigned to Arm(s): No calorie beverages | Intervention Type: BEHAVIORAL; Name: 2 water beverages per day; Assigned to Arm(s): Water

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
Brief Summary: The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).


Options:
A: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
B: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
C: Arm Label: Ezetimibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe, Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments
Brief Summary: Inappropriate antibiotic prescribing for acute respiratory infections (ARIs) persists despite decades of intervention efforts. Negative outcomes of inappropriate antibiotics include increased costs of care, adverse drug reactions, and rising prevalence of antibiotic-resistant bacteria. To address this public health problem, we apply the principles of commitment and consistency in an effort to influence clinician decision-making through the implementation of a low-cost behavioral "nudge" in the form of a simple public commitment device. Clinicians were asked to post in their exam room a signed letter indicating their commitments to reducing inappropriate antibiotic use for ARIs. Our hypothesis is that clinicians displaying the poster-sized commitment letters will decrease their inappropriate antibiotic prescribing for ARIs as compared to clinicians in the control condition (with no posted letter).


Options:
A: Arm Label: Posted commitment letter; Type: EXPERIMENTAL; Interventions: Other: Posted commitment letter | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Posted commitment letter; Assigned to Arm(s): Posted commitment letter
B: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
C: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
D: Arm Label: Intervention areas; Type: EXPERIMENTAL; Interventions: Other: Multifaceted information campaign | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multifaceted information campaign; Assigned to Arm(s): Intervention areas

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.


Options:
A: Intervention Type: DRUG; Name: Tolterodine ER 4mg QD; Assigned to Arm(s): N/A
B: Arm Label: BOTOX®; Type: EXPERIMENTAL; Interventions: Biological: BOTOX®, Drug: solifenacin placebo | Arm Label: solifenacin; Type: ACTIVE_COMPARATOR; Interventions: Biological: BOTOX®, Drug: solifenacin, Drug: Botox placebo (normal saline) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: BOTOX®, Drug: Botox placebo (normal saline), Drug: solifenacin placebo | Intervention Type: BIOLOGICAL; Name: BOTOX®; Assigned to Arm(s): BOTOX®, placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): solifenacin | Intervention Type: DRUG; Name: Botox placebo (normal saline); Assigned to Arm(s): placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin placebo; Assigned to Arm(s): BOTOX®, placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-3001a | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: DR-3001b | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: DR-3001a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: DR-3001b; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Fesoterodine (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Double-Blind)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial
Brief Summary: A double-blind randomized controlled trial to compare a shorter interval between the administration of mifepristone and misoprostol (simultaneous administration compared to 24hours from administration of mifepristone to receipt of the first dose of misoprostol) for termination of pregnancy up to 13-22 weeks of gestation. The investigators hypothesize that a shortened interval may achieve comparable efficacy in terminating pregnancy, whilst reducing the duration of the procedure and in turn, the duration of hospitalization.


Options:
A: Arm Label: ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen
B: Arm Label: Therapeutic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: Prophylactic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Prophylactic, Therapeutic
C: Arm Label: Mifepristone at home 24 hours before miso dosing starts; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Mifepristone and first dose of misoprostol simultaneously.; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone at home 24 hours before miso dosing starts | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Mifepristone and first dose of misoprostol simultaneously.
D: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase IV Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients
Brief Summary: This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet and Joins tablet in the treatment of osteoarthritis of the knee.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: acetaminophen extended release | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: acetaminophen extended release; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 002
B: Arm Label: LAYLA; Type: EXPERIMENTAL; Interventions: Drug: LAYLA tablet | Arm Label: JOINS; Type: ACTIVE_COMPARATOR; Interventions: Drug: JOINS tablet | Intervention Type: DRUG; Name: LAYLA tablet; Assigned to Arm(s): LAYLA | Intervention Type: DRUG; Name: JOINS tablet; Assigned to Arm(s): JOINS
C: Arm Label: MEDIC; Type: ACTIVE_COMPARATOR; Interventions: Other: Neuromuscular training (NEMEX-TJR), Drug: Paracetamol, Drug: Burana, Drug: Pantoprazole, Behavioral: Dietary counseling, Behavioral: Patient education, Other: Insoles | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information | Intervention Type: OTHER; Name: Neuromuscular training (NEMEX-TJR); Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Information; Assigned to Arm(s): Standard treatment | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Burana; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Dietary counseling; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Patient education; Assigned to Arm(s): MEDIC | Intervention Type: OTHER; Name: Insoles; Assigned to Arm(s): MEDIC
D: Arm Label: Tramadol Hydrochloride/Acetaminophen ER; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/Acetaminophen ER | Arm Label: Tramadol HCl/Acetaminophen IR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tramadol HCl/Acetaminophen IR | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen ER; Assigned to Arm(s): Tramadol Hydrochloride/Acetaminophen ER | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen IR; Assigned to Arm(s): Tramadol HCl/Acetaminophen IR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pediatric Behavioral Informatics to Prevent Cancer
Brief Summary: The goal of this study is to do formative research which will lead ultimately to the development of a computer-based system called Tailored Information for Diet and Exercise or TIDE for short. TIDE will target energy balance behaviors to prevent the onset of obesity in children. The system will be used by physicians and parents/primary care givers in pediatric primary care practices with the aim of improving parent-pediatrician interactions related to counseling and anticipatory guidance on energy balance behaviors. The aim of this study is to develop a one-two page, paper-pencil proxy questionnaire that is used to query the parent of the child in the waiting room and assesses topic areas related to energy balance behaviors (EBB). The questionnaire will be referred to as the energy balance behaviors questionnaire (EBB-Q). This will require focus groups, cognitive testing of the questionnaire, and survey administration.


Options:
A: Arm Label: Survey; Type: N/A; Interventions: N/A
B: Arm Label: Narrative (target); Type: EXPERIMENTAL; Interventions: Behavioral: Narrative | Arm Label: Narrative+ experiential (target); Type: EXPERIMENTAL; Interventions: Behavioral: Narrative, Behavioral: Experiential | Arm Label: Narrative (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Narrative | Arm Label: Narrative+ experiential (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Narrative, Behavioral: Experiential | Intervention Type: BEHAVIORAL; Name: Narrative; Assigned to Arm(s): Narrative (control), Narrative (target), Narrative+ experiential (control), Narrative+ experiential (target) | Intervention Type: BEHAVIORAL; Name: Experiential; Assigned to Arm(s): Narrative+ experiential (control), Narrative+ experiential (target)
C: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
D: Arm Label: Experimental 3; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar, Behavioral: Marketing | Arm Label: Experimental 2; Type: EXPERIMENTAL; Interventions: Behavioral: Marketing | Arm Label: Experimental 1; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New salad bar; Assigned to Arm(s): Experimental 1, Experimental 3 | Intervention Type: BEHAVIORAL; Name: Marketing; Assigned to Arm(s): Experimental 2, Experimental 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pediatric Behavioral Informatics to Prevent Cancer
Brief Summary: The goal of this study is to do formative research which will lead ultimately to the development of a computer-based system called Tailored Information for Diet and Exercise or TIDE for short. TIDE will target energy balance behaviors to prevent the onset of obesity in children. The system will be used by physicians and parents/primary care givers in pediatric primary care practices with the aim of improving parent-pediatrician interactions related to counseling and anticipatory guidance on energy balance behaviors. The aim of this study is to develop a one-two page, paper-pencil proxy questionnaire that is used to query the parent of the child in the waiting room and assesses topic areas related to energy balance behaviors (EBB). The questionnaire will be referred to as the energy balance behaviors questionnaire (EBB-Q). This will require focus groups, cognitive testing of the questionnaire, and survey administration.


Options:
A: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
B: Arm Label: Survey; Type: N/A; Interventions: N/A
C: Arm Label: HOME Plus Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: HOME Plus intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HOME Plus intervention; Assigned to Arm(s): HOME Plus Intervention
D: Arm Label: Healthy Children, Strong Families (first); Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Children, Strong Families, Behavioral: Child Safety | Arm Label: Child Safety (first); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Children, Strong Families, Behavioral: Child Safety | Intervention Type: BEHAVIORAL; Name: Healthy Children, Strong Families; Assigned to Arm(s): Child Safety (first), Healthy Children, Strong Families (first) | Intervention Type: BEHAVIORAL; Name: Child Safety; Assigned to Arm(s): Child Safety (first), Healthy Children, Strong Families (first)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.
Brief Summary: Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Intervention Type: BIOLOGICAL; Name: Stem cell therapy; Assigned to Arm(s): Group A, Group B
B: Arm Label: Stem Cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell, Drug: Filgrastime (G-CSF) | Arm Label: Standart therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standart therapy | Intervention Type: PROCEDURE; Name: Stem cell; Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Filgrastime (G-CSF); Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Standart therapy; Assigned to Arm(s): Standart therapy
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
D: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.
Brief Summary: Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.


Options:
A: Arm Label: Lower dose mesenchymal stem cell (MSC) injection; Type: EXPERIMENTAL; Interventions: Biological: Lower dose mesenchymal stem cell (MSC) injection | Arm Label: Higher dose MSC injection; Type: EXPERIMENTAL; Interventions: Biological: Higher dose MSC injection | Arm Label: (3) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Genetic: Placebo | Intervention Type: BIOLOGICAL; Name: Lower dose mesenchymal stem cell (MSC) injection; Assigned to Arm(s): Lower dose mesenchymal stem cell (MSC) injection | Intervention Type: GENETIC; Name: Placebo; Assigned to Arm(s): (3) Placebo | Intervention Type: BIOLOGICAL; Name: Higher dose MSC injection; Assigned to Arm(s): Higher dose MSC injection
B: Arm Label: Intramyocardial Injections; Type: EXPERIMENTAL; Interventions: Procedure: Intramyocardial injection | Arm Label: Intracoronary Injections; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intracoronary injection | Arm Label: Ischemic heart disease; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intramyocardial injection | Intervention Type: PROCEDURE; Name: Intramyocardial injection; Assigned to Arm(s): Intramyocardial Injections | Intervention Type: PROCEDURE; Name: Intracoronary injection; Assigned to Arm(s): Intracoronary Injections | Intervention Type: PROCEDURE; Name: Intramyocardial injection; Assigned to Arm(s): Ischemic heart disease
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
D: Arm Label: Peripheral; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor | Arm Label: Percutaneous intracoronary injection; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor, Procedure: Percutaneous intracoronary injection | Arm Label: Percutaneous intramyocardial injection; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor, Procedure: Percutaneous intramyocardial injection | Intervention Type: DRUG; Name: Granulocyte-colony stimulating factor; Assigned to Arm(s): Percutaneous intracoronary injection, Percutaneous intramyocardial injection, Peripheral | Intervention Type: PROCEDURE; Name: Percutaneous intracoronary injection; Assigned to Arm(s): Percutaneous intracoronary injection | Intervention Type: PROCEDURE; Name: Percutaneous intramyocardial injection; Assigned to Arm(s): Percutaneous intramyocardial injection

Answer: C